LOS ANGELES, Feb. 27, 2018 /PRNewswire/ -- Stellar
Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a
key protein utilized in multiple immunotherapy development
pipelines targeting Alzheimer's, diabetes, lupus and cancers, among
other diseases, today announced that Michael Kennedy has joined the company to lead
the company's manufacturing activities.
Kennedy, who has extensive bioprocessing experience over the
last 26 years related to advancing biopharmaceutical products from
clinical to commercial manufacturing, will manage the company's
optimization and scale-up activities, and oversee manufacturing and
purification processes at Stellar's California manufacturing facility, which
operates under current Good Manufacturing Practices (cGMP).
"Michael is an excellent addition to our manufacturing team. His
experience in process optimization, new facility engineering and
quality system implementation will further enhance Stellar's
ability to expand production of GMP grade KLH for the immunotherapy
and diagnostic markets," said Gregory T.
Baxter, PhD, Stellar Executive Vice President of Corporate
Development.
Prior to joining Stellar, Kennedy led manufacturing teams and
process engineering at Shire, Inc., Symex and Amgen, Inc. He has
also consulted on complex biopharmaceutical manufacturing
operations and regulatory submissions. He has a Master's Degree in
Technology Management from Pepperdine
University, a Bachelor's Degree from San Jose State University and is a California State
Board of Pharmacy Designated Representative (Exemptee).
About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in
sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an
important immune-stimulating protein used in wide-ranging
therapeutic and diagnostic markets. KLH is both an active
pharmaceutical ingredient (API) in many new immunotherapies
(targeting cancer, immune disorders, Alzheimer's and inflammatory
diseases) as well as a finished product for measuring immune
status. Stellar is unique in its proprietary methods, facilities,
and KLH technology. The company is committed to meeting the growing
demand for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based
active immunotherapies. Stellar KLH is a trademark of Stellar
Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking Statements
This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements may be identified by the use of
words such as "anticipate," "believe," "plan," "estimate,"
"expect," "intend," "may," "will," "would," "could," "should,"
"might," "potential," or "continue" and variations or similar
expressions. Readers should not unduly rely on these
forward-looking statements, which are not a guarantee of future
performance. There can be no assurance that forward-looking
statements will prove to be accurate, as all such forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results or future events to differ
materially from the forward-looking statements. Such risks include,
but may not be limited to: general economic and business
conditions; technology changes; competition; changes in strategy or
development plans; availability of funds and resources; anticipated
requirements for operating capital; governmental regulations and
the ability or failure to comply with governmental regulations;
changes in trade policy and international law; the timing of
Stellar's or its partners' anticipated results, including in
connection with clinical trials; the ability to meet the goals of
Stellar's joint ventures and strategic partnerships; and other
factors referenced in Stellar's filings with securities regulators.
For a discussion of further risks and uncertainties related to the
Stellar's business, please refer to Stellar's public company
reports filed with the U.S. Securities and Exchange Commission and
the British Columbia Securities Commission. All forward-looking
statements are made as of the date hereof and are subject to
change. Except as required by law, Stellar assumes no obligation to
update such statements. This press release does not constitute an
offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United
States.
View original
content:http://www.prnewswire.com/news-releases/stellar-biotechnologies-appoints-bioprocess-expert-to-lead-manufacturing-300604297.html
SOURCE Stellar Biotechnologies, Inc.